Skip to main content
SpringerLink
Log in

Carboplatin/irinotecan/paclitaxel

Various toxicities: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Takatori E, et al. Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy. Journal of Obstetrics and Gynaecology Research 39: 1354-1358, No. 8, Aug 2013. Available from: URL: http://doi.org/10.1111/jog.12062 - Japan

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carboplatin/irinotecan/paclitaxel. Reactions Weekly 1506, 10 (2014). https://doi.org/10.1007/s40278-014-1447-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-1447-8

Search

Navigation